

Registered charity number: 1185148

Report of the Trustees and
Unaudited Financial Statements
for the year ended 31 March 2025

for British Lymphology Society CIO

British Lymphology Society CIO
Contents of the Financial Statements
for the year ended 31 March 2025

	Page
Information page	1
Report of the Trustees	2
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12

**British Lymphology Society CIO
Information Page
for the year ended 31 March 2025**

Registered Charity Number

1185148

Trustees

Co Chairperson - Yolande Borthwick (from November 2024)

Co Chairperson - Lorraine Brown (from November 2024)

Vice Chairperson - Margaret Sneddon (from November 2024)

Treasurer - Peter Hooper-Smith

Trustees -

Rebecca Elwell

Rachael Hutton

Devina Dicarlo (resigned 04/03/25)

Tamara Kosevic

Katie Riches

Carla Zanichelli Vives

Co-opted Trustee & BLS editor

Cheryl White

BLS Scientific Committee chair & Co-opted trustee

Emma Underwood

Independent Examiner

J Bardolph ACA, FCCA, BFP

Accountably Ltd

1st Floor, Unit 12

Compass Point

Ensign Way

Hamble

Southampton

Hampshire

SO31 4RA

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity registered with the Charity Commission on 3 September 2019, under registration number 1185148 and is a charitable incorporated organisation - CIO.

Risk management

The BLS maintains a proactive approach to risk through regular assessments with key stakeholders and project leads, systematically mapping potential financial, operational, regulatory, and reputational risks. Risks are evaluated in line with the Charity Commission's Risk Management Framework (CC26), with strengthened financial controls and enhanced data and cyber security measures implemented over the past year. We are pleased to report that no incidents occurred during the year.

Policies and Procedures

The BLS has created and updated the following policies this year:

- Anti-Fraud, Bribery & Corruption Policy (approved board meeting 9th July 2025)
- IT Security & Clear Desk Policy (approved board meeting 7th May 2025)
- Gift and Hospitality Policy (approved board meeting 7th May 2025)
- Accepting, declining donation policy (approved board meeting 7th May 2025)
- Grant application and monitoring policy (approved board meeting 7th May 2025)
- Use of BLS Debit and Authentication Cards Policy and Procedure (approved 5th February 2025)

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

Our mission is to raise the standard of lymphoedema care across the UK. Over the past year we have continued to strengthen our role as a professional voice, shaping best practice and expanding support for those living with lymphoedema, and those who treat the condition. This report showcases our achievements and sets the stage for an exciting year ahead.

Our Priorities for Delivery

In September 2024 we approved our new strategic plan:

- **Purpose:** We strive for better outcomes for people with lymphoedema, to enable them to live full and active lives.
- **Our Vision:** To be the most trusted and accessible source of expert knowledge on lymphoedema; a strong voice, advocating for the lymphoedema community.
- **Our Values:** We celebrate the experience and passion of our community and seek to build genuine relationships by empowering people to be actively involved in our mission.
- **Our Mission:** To produce the highest quality content, making it readily available through impartial and evidence-based resources. To campaign for equity of access to effective treatment and to support patients and practitioners.

At our annual conference in October 2024, delegates were invited to provide feedback on the future direction of BLS through Stop/Start/Continue discussions, ensuring that the charity's activities align with the needs and priorities of its members. Insights from this feedback contributed to helping us to finalise our strategic priorities for 2025-28:

- Producing high quality evidence-based resources and educational content
- Driving continuous improvement in treatment and equitable access to lymphoedema services through our campaigns and educational outputs
- Supporting and strengthening our campaigns by ensuring they are as data-driven as possible
- Strengthening our engagement and collaborations to achieve better outcomes for all
- Diversifying and growing our income

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

ACHIEVEMENTS AND PERFORMANCE

As Co-Chairs of the British Lymphology Society, we are delighted to welcome you to our Annual Report for 2024–25. This year marks a particularly exciting milestone for BLS, as we celebrate 40 years since the society was established, originally as the British Lymphoedema Interest Group (BLIG). Over four decades, BLS has grown into a vibrant professional community, driving awareness, education, research, and standards of care for lymphoedema across the UK.

This year marks a particularly exciting milestone for BLS, as we celebrate 40 years since the society was established, originally as the British Lymphoedema Interest Group (BLIG). Over four decades, BLS has grown into a vibrant professional community, driving awareness, education, research, and standards of care for lymphoedema across the UK.

The past year has been full of achievement. Our Conference 2024 brought together over 200 delegates to share knowledge, launch key clinical guidance, and celebrate innovation in lymphoedema care. We have extended our engagement through Lymphaletics and youth-focused initiatives and increased participation in Lymphoedema Awareness Week, with global reach through webinars and interactive sessions. We have also strengthened our advocacy and partnerships, working with organisations such as NICE, Macmillan Cancer Support, Cancer Alliances, and the Transforming Cancer Services Team (TCST), and engaging high-profile supporters to champion research and awareness.

Looking ahead, we are particularly excited about our upcoming free “Introduction to Lymphoedema” study day, designed to provide non-specialist healthcare professionals with essential knowledge and practical skills. This, along with plans to further expand youth and family outreach and celebrate our 40th anniversary, promises to make 2025–26 another landmark year for BLS.

None of this would be possible without our dedicated trustees, staff, corporate partners, members, and supporters. Your commitment continues to drive the society forward, enabling us to innovate, extend our reach, and provide meaningful support to patients and healthcare professionals alike.

Thank you, Lorraine and Yolande

Celebrating 40 Years of BLS

2025 marks an exciting milestone for BLS, as we celebrate 40 years since the organisation was established, originally as the British Lymphoedema Interest Group (BLIG). The early pioneers who founded BLIG laid the foundations for lymphoedema treatment in the UK, and through BLIG and its successor, BLS, they built a strong professional community dedicated to improving care. Over four decades, this community has driven awareness of lymphoedema, developed structured education programmes, supported research, and established standards of treatment.

Conference 2024: Racing to Success

The BLS Conference is our largest annual event and a true highlight in the calendar, bringing together professionals, researchers, and partners from across the UK and beyond. In October 2024, over 200 delegates gathered at Chester Racecourse for an inspiring programme of education, collaboration, and innovation. Kindly sponsored by Haddenham Healthcare Ltd, Essity, Medi UK, and Juzo Ltd, the event was a real achievement for BLS and the wider lymphoedema community.

The programme had a strong focus on Breast Cancer Related Lymphoedema (BCRL), featuring international expertise from Cheryl Brunelle (Massachusetts General Hospital) and Hildegard Reul-Hirche (Brisbane), alongside leading UK speakers including Professor Amit Goyal on axillary management and breast reconstruction, and Consultant Clinical Oncologist Daljit Gahir on advances in breast cancer treatments. Additional sessions covered research into genital lymphoedema, lymphatic dysfunctions, and head and neck care, complemented by a rich poster programme and three new BLS resource launches.

Beyond the scientific sessions, delegates valued the opportunity to engage with 31 corporate partners and several patient charities at the Meet the Exhibitors Buffet. Feedback was overwhelmingly positive, with one delegate commenting it was “by far the best conference”.

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

Plans are underway for Conference 2025, which will mark a special anniversary year for BLS, set to be our most memorable celebration yet.

Key Achievements and Highlights

New Guidance and Resources

A major achievement at the 2024 Conference was the launch of several important new resources for clinicians. In partnership with Omniamed/Wounds UK, BLS introduced updated guidance on compression, alongside a new document on Manual Lymphatic Drainage (MLD) and guidance relating to heart failure. These evidence-based resources will support best practice and ensure consistency in care across services.

In addition, BLS unveiled a curated list of free training opportunities for members, bringing together high-quality courses designed to strengthen knowledge and skills. This list is now available to all members as part of our commitment to widening access to professional development.

Lymphoedema Awareness Week 2025

Lymphoedema Awareness Week (3–7 March 2025) was one of our most visible campaigns to date. The week featured a programme of webinars, strong media presence, helping to raise awareness and broaden understanding of lymphoedema among both professionals and the public.

In addition to webinars addressing general lymphoedema information and treatment we focused part of the activity on different types of cancer associated with lymphoedema this year. Key webinars broadcast included those on lymphoedema as a consequence of breast, skin and pelvic and genital cancers.

We had great support in promoting these from related charities, such as Breast Cancer Now, Pelvic Radiation Disease Association and Melanoma UK. These were useful reminders that ongoing vigilance is needed because although advances in cancer treatment have greatly improved, enabling more people to live longer, many continue to develop lymphoedema post treatment.

We were also delighted to once again be supported by the Lymphatic Education and Research Network and featured in their video promoting global awareness on World Lymphoedema Day on 6th March. Some of the webinars are available to watch on our YouTube Channel for anyone who missed them!

In addition to the events organised centrally, a key part of the success of the awareness campaign is the work of our members and corporate partners who run educational events, set up information stands in public places and share information on social media. Getting the messages out to the community and through these networks depends on the commitment and passion of so many of our members and supporters. Thank you all!

National Representation and Outreach

BLS has maintained a strong presence at key national events throughout the year, engaging healthcare professionals and promoting membership. Highlights included the National Lymphoedema Conference in London, Wound Care Today in Telford, the Society of Tissue Viability event in Bradford the Leg Club Conference in Worcester, and the online Legs Matter Roadshows. These activities provide valuable opportunities to share expertise, raise awareness of lymphoedema, and support professional development across the healthcare community.

Launch of new resources and documents

In February 2025, BLS co-chaired and represented the society at the 12th National Lymphoedema Conference in London. The event was a great success, sparking lively discussion and providing the platform to launch several key BLS documents, including the Lower Limb Inflammatory Pathway (formerly the Red Leg Pathway) and the Heart Failure and Compression guidance. All were met with great enthusiasm from delegates.

Alongside these launches, we also released an updated version of the BLS Limbstat limb-volume tool, further enhancing accuracy and usability for clinicians. Together, these resources strengthen day-to-day practice and reinforce BLS's role in leading the development of evidence-based standards in lymphoedema care.

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

Lymphaletics 2024: A Family Celebration

In September 2024, the BLS Children & Young People's Lymphoedema Special Interest Group (BLSCLSIG) hosted Lymphaletics at Bracknell Leisure Centre—a fully funded, family-centred event that brought together children and young people living with lymphoedema, along with their families. The day combined fun activities such as soft play, sports, dance workshops, and entertainment with opportunities for families to engage with industry stands, public health initiatives, and specialist clinicians.

The educational programme was equally powerful, with young people sharing their personal experiences of living with lymphoedema, and a lively Q&A led by Professor Kristiana Gordon and Professor Mortimer. The afternoon culminated in the spirited Lymphaletics games, complete with medals, certificates, and healthy lifestyle goody bags.

Feedback was unanimously positive, with the event hailed as both a community success and a meaningful source of support for families. Thanks to the dedicated team of clinicians, volunteers, and partners, including JUZO, who kindly provided uniforms, the event had a profound impact on all who attended.

Launch of first free “Introduction to Lymphoedema” study day This year, BLS launches its first free “Introduction to Lymphoedema” study day, designed specifically for non-specialist healthcare staff. The event will give an accessible overview of lymphoedema, its impact, and the principles of management, equipping participants with the knowledge to better identify and support patients.

As the first initiative of its kind from BLS, the study day reflects our commitment to widening awareness, strengthening early recognition, and ensuring more patients receive timely, effective care. We are very excited about delivering this event and hope that it will be the first of many.

Growing our Income

We are pleased to report a notable increase in sponsorship from our valued corporate partners over the past year. This growth in income has directly enabled us to broaden our reach by offering additional delegate places at our annual conference, funding our first study day and funding the lymphoedema awareness webinars, thus extending access, sharing knowledge, and deepening engagement across our community. In line with our commitment to sustainability and good governance, we carefully reinvest the majority of our income into the charity's operations and outputs, while maintaining a prudent reserve to support long-term stability.

Trustee Recognition

We are proud to share that several of our trustees have been recognised with awards for their outstanding contributions to lymphoedema care and service. These accolades reflect not only their dedication to their roles, but also their unwavering commitment to improving outcomes for patients. The awards acknowledge a range of achievements, including exceptional impact on patient care, innovative service development, and going above and beyond in advancing the management of lymphoedema. This recognition is a testament to the passion and leadership our trustees bring to the organisation and to the wider lymphoedema community.

Congratulations to Rachael Hutton for receiving the Queen's award, Lorraine Brown for receiving the Chronic Oedema Silver Nurse Award, and Nicole Faccio and the BLS Scientific Committee's Fran Campbell for their Legs Matter.

Changemaker awards: congratulations too, to Cheryl White who passed her Leadership for Allied Health Professionals qualification with a distinction.

Yolande Borthwick was honoured with an invitation to a reception at Buckingham Palace hosted by Their Majesties The King and Queen, recognising community-based initiatives that raise awareness about cancer.

News & Views: Sharing Knowledge and Driving Practice

BLS's quarterly publication, News & Views, continues to be a vital resource for healthcare professionals working in lymphoedema care. The newsletter supports members by sharing evidence-based guidance, updates on clinical practice, and insights into research and innovation in the field.

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

Key features include summaries of clinical enquiries, promotion of ongoing research studies, and the results of member surveys, helping to inform practice and support the development of new resources. News & Views also highlights updates to clinical pathways and best-practice guidance, as well as educational materials designed to strengthen professional development across the membership.

Through this publication, BLS fosters engagement and collaboration, ensuring that members' insights and feedback help shape the society's priorities and resources. It remains an essential tool in advancing knowledge, raising standards, and promoting excellence in lymphoedema care.

Voice, Advocacy & Partnerships

BLS continues to influence public policy and raise the profile of lymphoedema through strategic collaborations with organisations including NICE, Macmillan Cancer Support, the Pelvic Radiation Disease Association, Cancer Alliances, and TCST. These partnerships help shape standards of care, support research, and enhance awareness of lymphoedema across the healthcare system.

The charity continues to be recognised as a trusted source of expertise on lymphoedema, responding to press enquiries and contributing to national conversations about the condition. This year, we were pleased to provide accurate information to journalists and media outlets seeking specialist insight.

This year we also challenged misinformation, responding to inaccuracies on BBC Radio 2's Jeremy Vine Show. By setting the record straight, we strengthened our reputation as the leading authority on lymphoedema and reinforced our commitment to clear, evidence-based information.

The BLS was invited to attend an event in support of the St George's Lymphoedema Research Fund, which brought together a wide range of supporters, including high-profile figures such as Dame Judi Dench and Dame Joanna Lumley. Their presence helped shine a spotlight on lymphoedema research and the importance of continued investment.

The BLS maintains collaborative relationships with international lymphoedema associations and charities like ours, and shares best practice, new developments and information with our international colleagues.

Scientific Committee (BLSSC) Report 2024 - 25

Committee Members:

Emma Underwood (Chair) Fran Campbell (Vice Chair), Dr Ambreen Chohan, Prof Kristiana Gordon, Dr Garry Cooper, Dr Catherine O'Leary, Dr Catherine Mitchell, Patryk Gawrysiak, Preksha Vivekanandan (Honorary), Laura Henry (Honorary), Rebecca Elwell (Co-opted Conference Organiser).

During 2024/25 the Scientific Committee (SC) met online to continue to support the BLS Board with the overall aim of promoting research and service development in the field of lymphoedema in the UK.

Changes to membership:

In recognition of Rebecca Elwell's continued support of the SC and the valuable role she plays as conference organiser it was agreed that she should be co-opted to the SC allowing her to remain on the SC indefinitely, whilst she continues in her conference liaison role. This has allowed an additional member to be recruited to the SC and it was agreed that this could be offered as either a full or honorary member position. We are pleased to have two honorary members on the SC which furthers the SC's goal of nurturing early career researchers.

Key document updates:

The SC terms of reference have been reviewed and updated and the LDRG policy was reviewed and updated at the BLS Conference 2024.

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

The SC managed the abstract submission process and anonymous peer review selection for the 2024 conference, attracting 26 submissions. The marking criteria for abstract submissions has been reviewed to further ensure that the scientific content of the BLS conference is robust. The marking criteria and process for both the poster and oral presentations has been reviewed and streamlined.

Face to face poster presentations were introduced and were well received, allowing delegates the opportunity to meet presenters and discuss their work in more detail. The SC was responsible for scoring of both the oral and poster presentations at the conference and awarding best novice and experienced presenter awards.

The SC stand attracted a lot of footfall allowing the SC to encourage novice researchers, answer questions and promote SC initiatives.

The Case Report Competition

The case report competition winner was Susan Witt who will be supported to publish the case report in the Chronic Oedema Supplement.

The Lymphoedema Research Development Grant (LRDG)

We are pleased to announce that a team led by Susan Witt and including Professor Vaughan Keeley, Professor Neil Piller and Associate Professor Raoul van Loon following commendations from the SC on the application, have been awarded the £10,000 grant for a feasibility study 'Measuring the direct impact of temperature on the lymphatic system and mechanical properties of skin': a feasibility study (pending ethical approval).

Other contributions

Requests for the BLS to promote external research studies: the SC advises the Board. News & Views - SC members continue to contribute articles to the newsletter on a range of research and clinical evidence publication topics.

Clinical Queries: SC members have regularly provided or signposted to, scientific or clinical advice which are submitted to BLS. To widen the reach of this advice to the membership the queries and responses are now published in News and Views.

Clinical advisors to external bodies: SC members represent the BLS as clinical experts and advisors to bodies such as NICE when clinical reviews relevant to Lymphoedema are being conducted or when national/international guidelines are being created.

Contributing to specific BLS workstreams: Members of the SC have been part of specific working subgroups of the Board.

International networking and support: The SC chair advised the research lead for LEARN on documents and processes on the LRDG to enable development of a similar program with LEARN.

FINANCIAL REVIEW AND RESERVES POLICY

In 2025, the BLS generated £223k of income, broadly in line with 2024 (£226k). Our income streams comprised:

- Conference income £135k – £13k lower than 2024, reflecting slightly reduced ticket and exhibitor sales compared with the exceptionally popular October 2023 conference, which was the first in-person event post-COVID.
- Membership subscriptions £66k – £8k higher than 2024, driven by growth in Corporate Membership.
- Advertising income £11k – slightly below 2024 (£14k).
- Bank interest £10k – up from £6k in 2024, due to higher interest rates.

British Lymphology Society CIO
Report of the Trustees
for the year ended 31 March 2025

Expenditure in 2025 totalled £195k, which was £23k lower than 2024. The reduction was mainly due to the one-off £20k rebranding project in 2024, which was not repeated. Key points include:

- Administration costs £62k – £9k higher than 2024, reflecting the review of our constitution and strategy.
- Wages & expenses – £4k higher, to support the Charity’s expanding activity.
- Conference expenditure – £9k lower than 2024.
- Website and Newsletter costs – reduced by £3k, achieved through streamlined IT systems and reduced printing.

Careful cost management has ensured that despite investment in strategic initiatives, our overall spend remains lower than the previous year. This provides a stable financial platform to support the BLS’s charitable mission going forward.

The reserves policy of the charity to maintain unrestricted funds which have not been designated for a specific use of twelve months’ expenditure. The policy ensures that reserves at this level will be sufficient so that in the event of a significant drop in funding, that the trustees will be able to continue the charity’s activities while consideration is given to ways in which additional funds may be raised. The twelve months’ expenditure level of reserves was achieved throughout the financial year.

2025-26

The BLS is entering an exciting year, building on recent achievements and marking 40 years since the society was established. Key priorities for 2025–26 include:

- Website and brand: Enhancing online presence and accessibility to better serve members and the wider lymphoedema community.
- Working closely with patient charities: Strengthening collaborations to raise awareness, improve patient support, and amplify advocacy efforts.
- Expanding the free Study Day series: Continuing to provide accessible education for non-specialist healthcare staff and extending professional development opportunities.
- 40th Birthday Celebrations: Commemorating four decades of BLS’s contributions to lymphoedema care, research, education, and professional community building.

Thank You

We are deeply grateful to our passionate trustees, staff, corporate members, partners, and supporters. Your dedication, expertise, and commitment have enabled BLS to grow from strength to strength, advancing lymphoedema care, education, and research across the UK.

The policy of the charity to maintain unrestricted funds which have not been designated for a specific use of twelve months’ expenditure. The policy ensures that reserves at this level will be sufficient so that in the event of a significant drop in funding, that the trustees will be able to continue the charity’s activities while consideration is given to ways in which additional funds may be raised. The twelve months’ expenditure level of reserves was achieved throughout the financial year.

INDEPENDENT EXAMINER

Jonathan Bardolph ACA,FCCA & BFP has been re-appointed as independent examiner for the ensuing year.

Approved by order of the board of trustees on.....**17 Sep 2025**
and signed on its behalf by:



.....
Lorraine Brown

British Lymphology Society CIO
Independent Examiner's Report to the Trustees
for the year ended 31 March 2025

I report to the trustees on my examination of the accounts of the above charity for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

1. the accounting records were not kept in accordance with section 130 the Charities Act; or
2. the accounts did not accord with the accounting records; or
3. the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

J Bardolph

.....
J Bardolph ACA, FCCA, BFP
Independent Examiner

Accountably Ltd
1st Floor, Unit 12
Compass Point
Ensign Way
Hamble
Southampton
Hampshire
SO31 4RA

18 Sep 2025.....

British Lymphology Society CIO
Statement of Financial Activities
for the year ended 31 March 2025

	Notes	Unrestricted fund £	Restricted fund £	2025 Total funds £	2024 Total funds £
INCOMING RESOURCES					
Incoming resources from generated funds					
Voluntary income	2	66,311	-	66,311	58,283
Charitable activities	3	146,133	-	146,133	161,624
Investment income	4	9,649	560	10,209	6,195
Total incoming resources		222,093	560	222,653	226,102
RESOURCES EXPENDED					
Charitable activities	5	190,758	-	190,758	212,271
Governance costs	6	4,762	-	4,762	5,775
Total resources expended		195,520	-	195,520	218,046
NET INCOMING RESOURCES and net income for the year		26,573	560	27,133	8,056
Net movement in funds		26,573	560	27,133	8,056
RECONCILIATION OF FUNDS					
Total funds brought forward	10	267,063	22,660	289,723	281,667
TOTAL FUNDS CARRIED FORWARD	10	293,636	23,220	316,856	289,723

The Statement of Financial Activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes form part of these financial statements.

British Lymphology Society CIO
Balance Sheet
as at 31 March 2025

	Notes	2025 Total funds £	2024 Total funds £
FIXED ASSETS			
Intangible fixed assets	7	23,910	-
CURRENT ASSETS			
Debtors	8	93,962	49,021
Cash at bank		<u>312,903</u>	<u>379,229</u>
		406,865	428,250
CREDITORS			
Amounts falling due within one year	9	<u>(113,919)</u>	<u>(138,527)</u>
NET CURRENT ASSETS		292,946	289,723
NET ASSETS		<u>316,856</u>	<u>289,723</u>
FUNDS			
	10		
Unrestricted funds:		293,636	267,063
Restricted funds		23,220	22,660
TOTAL FUNDS		<u>316,856</u>	<u>289,723</u>

17 Sep 2025

The financial statements were approved by the Board of Trustees on and were signed on its behalf by:

Yolande Borthwick

.....

Chairperson - Yolande Borthwick

P Hooper-Smith

.....

Treasurer - Peter Hooper-Smith

The notes form part of these financial statements.

1 ACCOUNTING POLICIES

The accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to the accounts. The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective January 2019.

General funds represent the funds of the charity that are not subject to any restrictions regarding their use and are available for application for general purposes. Funds designated for a particular purpose by the charity are also unrestricted. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those associated with the governance arrangements of the charity.

Website development	20% straight line
---------------------	-------------------

The charity is exempt from corporation tax on its charitable activities.

12

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2025

3 CHARITABLE ACTIVITIES	Unrestricted funds	Restricted funds	Total funds 2025	Total funds 2024
	£	£	£	£
Conference	135,082	-	135,082	147,588
Advertising and other services	11,051	-	11,051	14,036
	<hr/>	<hr/>	<hr/>	<hr/>
	146,133	-	146,133	161,624
	<hr/>	<hr/>	<hr/>	<hr/>
4 INVESTMENT INCOME	Unrestricted funds	Restricted funds	Total funds 2025	Total funds 2024
	£	£	£	£
Interest receivable	9,649	560	10,209	6,195
	<hr/>	<hr/>	<hr/>	<hr/>
5 EXPENDITURE - Charitable activities	Unrestricted funds	Restricted funds	Total funds 2025	Total funds 2024
	£	£	£	£
Office and administration costs	62,405	-	62,405	52,871
Website, computer and internet costs	2,444	-	2,444	5,282
Newsletter	3,793	-	3,793	5,200
Conference	89,647	-	89,647	98,868
Promotional items and surveys	3,706	-	3,706	25,620
Wages and expenses	28,763	-	28,763	24,430
	<hr/>	<hr/>	<hr/>	<hr/>
	190,758	-	190,758	212,271
	<hr/>	<hr/>	<hr/>	<hr/>
6 EXPENDITURE - Governance costs	Unrestricted funds	Restricted funds	Total funds 2025	Total funds 2024
	£	£	£	£
Book-keeping	569	-	569	499
Independent examiner	1,800	-	1,800	1,740
Insurance	1,036	-	1,036	1,359
Committee meetings	1,321	-	1,321	2,025
Exchange differences	36	-	36	152
	<hr/>	<hr/>	<hr/>	<hr/>
	4,762	-	4,762	5,775
	<hr/>	<hr/>	<hr/>	<hr/>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2025

7 INTANGIBLE FIXED ASSETS

	2025	Total
	£	£
Cost		
At 1 April 2024	-	-
Additions	23,910	23,910
Disposals	-	-
At 31 March 2025	<u>23,910</u>	<u>23,910</u>
Amortisation		
At 1 April 2024	-	-
Charge for the year *	-	-
On disposals	-	-
At 31 March 2025	<u>-</u>	<u>-</u>
Net book value		
At 31 March 2025	<u>23,910</u>	<u>23,910</u>
At 31 March 2024	<u>-</u>	<u>-</u>

* The trustees have decided not to amortise in this period as development costs are ongoing.

8 DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	2025	2024
	£	£
Trade debtors	66,935	27,245
Other debtors	27,027	21,776
	<u>93,962</u>	<u>49,021</u>

9 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	2025	2024
	£	£
Trade creditors	108	9,607
Deferred income	109,615	124,874
Accrued charges	4,196	4,046
	<u>113,919</u>	<u>138,527</u>

10 MOVEMENT ON UNRESTRICTED AND RESTRICTED FUNDS

	Balance at 1	Incoming	Outgoing	Transfers	Balance at
	April	resources	resources	between	31 March
	2024			funds	2025
	£	£	£	£	£
Unrestricted					
General fund	267,063	222,093	(195,520)	-	293,636
Restricted fund:					
Scientific research	22,660	560	-	-	23,220
	<u>289,723</u>	<u>222,653</u>	<u>(195,520)</u>	<u>-</u>	<u>316,856</u>

British Lymphology Society CIO
Notes to the Financial Statements
for the year ended 31 March 2025

11 ANALYSIS OF NET ASSETS BETWEEN FUNDS	Intangible fixed assets £	Net current assets £	Total £
Unrestricted:			
General fund	23,910	269,726	293,636
Restricted:			
Scientific research	-	23,220	23,220
	<u>23,910</u>	<u>292,946</u>	<u>316,856</u>

12 OTHER BENEFITS RECEIVED BY THE CHARITY

We are grateful to our corporate members for their generosity and their support in the 2024 conference. In addition, thank you to all who sponsor us in formal and informal ways.

13 TRUSTEES REMUNERATION AND EXPENSES

The following trustees received reimbursement of expenses during the year:

	£
K Riches	69
M Sneddon	599
R Hutton	404
R Elwell	223
L Brown	611
C White	2,105
Y Borthwick	760
P Hooper-Smith	535
E Underwood	608

No trustee nor anyone connected with them received any remuneration during the period in respect of their services as trustees.



Issuer Accountably Ltd

Document generated Wed, 17th Sep 2025 15:56:02 BST

Document fingerprint 7278fab069e2d558b5545bc6f22438e0

Parties involved with this document

Document processed	Party + Fingerprint
Wed, 17th Sep 2025 15:58:44 BST	Mr Peter Hooper-Smith - Signer (c8a7630d7bf9d105c08373b9bc3c535a)
Wed, 17th Sep 2025 16:13:08 BST	Mrs Lorraine Brown - Signer (a272e3b0a92a3521f3a96a136c921385)
Wed, 17th Sep 2025 20:24:42 BST	Mrs Yolande Borthwick - Signer (cc3ebb36a8722eca10098efe2b804e99)

Audit history log

Date	Action
Wed, 17th Sep 2025 15:56:02 BST	Envelope generated with fingerprint ced1d75e6efad90de2fbf7dec b7fd614 (35.176.231.177)
Wed, 17th Sep 2025 15:56:02 BST	Document generated with fingerprint 7278fab069e2d558b5545bc6f22438e0. (35.176.231.177)
Wed, 17th Sep 2025 15:56:02 BST	Mr Peter Hooper-Smith has been assigned to this envelope. (35.176.231.177)
Wed, 17th Sep 2025 15:56:02 BST	Mrs Lorraine Brown has been assigned to this envelope. (35.176.231.177)
Wed, 17th Sep 2025 15:56:02 BST	Mrs Yolande Borthwick has been assigned to this envelope. (35.176.231.177)
Wed, 17th Sep 2025 15:56:02 BST	Envelope has been set to automatically remind the active signer every 2 day(s). (35.176.231.177)
Wed, 17th Sep 2025 15:56:10 BST	Envelope generated
Wed, 17th Sep 2025 15:56:10 BST	Sent the envelope to Mr Peter Hooper-Smith for signing
Wed, 17th Sep 2025 15:56:11 BST	Document emailed to party email
Wed, 17th Sep 2025 15:57:40 BST	Mr Peter Hooper-Smith viewed the envelope (31.94.12.94)
Wed, 17th Sep 2025 15:58:44 BST	Mr Peter Hooper-Smith signed the envelope (31.94.12.94)
Wed, 17th Sep 2025 15:58:44 BST	Sent the envelope to Mrs Lorraine Brown for signing (31.94.12.94)
Wed, 17th Sep 2025 15:58:44 BST	Document emailed to party email
Wed, 17th Sep 2025 16:12:14 BST	Mrs Lorraine Brown viewed the envelope (208.127.199.47)
Wed, 17th Sep 2025 16:12:20 BST	Mrs Lorraine Brown viewed the envelope (62.252.191.196)
Wed, 17th Sep 2025 16:13:08 BST	Mrs Lorraine Brown signed the envelope (208.127.199.47)

Wed, 17th Sep 2025 16:13:09 BST	Sent the envelope to Mrs Yolande Borthwick for signing (208.127.199.47)
Wed, 17th Sep 2025 16:13:09 BST	Document emailed to party email
Wed, 17th Sep 2025 20:23:09 BST	Mrs Yolande Borthwick viewed the envelope (86.129.120.64)
Wed, 17th Sep 2025 20:23:22 BST	Mrs Yolande Borthwick viewed the envelope (62.252.232.5)
Wed, 17th Sep 2025 20:24:42 BST	Mrs Yolande Borthwick signed the envelope (86.129.120.64)
Wed, 17th Sep 2025 20:24:42 BST	This envelope has been signed by all parties (86.129.120.64)



Issuer Accountably Ltd

Document generated Thu, 18th Sep 2025 11:04:11 BST

Document fingerprint 4f643267cd15d746c92ec64818ea3098

Parties involved with this document

Document processed	Party + Fingerprint
Thu, 18th Sep 2025 11:18:55 BST	Jonathan Bardolph - Signer (06f1d2141b79c190f86752bc606ec949)
Thu, 18th Sep 2025 11:18:55 BST	Kirsty Lovett - Copied In (d220247e0e014297174fb0b6b47f8dd7)

Audit history log

Date	Action
Thu, 18th Sep 2025 11:04:11 BST	Envelope generated with fingerprint 71c6b2f8884b9fa227d19356d8225333 (35.176.231.177)
Thu, 18th Sep 2025 11:04:11 BST	Document generated with fingerprint 4f643267cd15d746c92ec64818ea3098. (35.176.231.177)
Thu, 18th Sep 2025 11:04:11 BST	Jonathan Bardolph has been assigned to this envelope. (35.176.231.177)
Thu, 18th Sep 2025 11:04:11 BST	Kirsty Lovett has been assigned to this envelope. (35.176.231.177)
Thu, 18th Sep 2025 11:04:11 BST	Envelope has been set to automatically remind the active signer every 1 day(s). (35.176.231.177)
Thu, 18th Sep 2025 11:06:28 BST	Envelope generated
Thu, 18th Sep 2025 11:06:28 BST	Sent the envelope to Jonathan Bardolph for signing
Thu, 18th Sep 2025 11:06:30 BST	Document emailed to party email
Thu, 18th Sep 2025 11:18:27 BST	Jonathan Bardolph viewed the envelope (51.195.204.129)
Thu, 18th Sep 2025 11:18:55 BST	Jonathan Bardolph signed the envelope (51.195.204.129)
Thu, 18th Sep 2025 11:18:56 BST	Sent the envelope to Kirsty Lovett for signing (51.195.204.129)
Thu, 18th Sep 2025 11:18:56 BST	This envelope has been signed by all parties (51.195.204.129)
Thu, 18th Sep 2025 11:18:56 BST	Document emailed to party email